GSK agreed to acquire Nuvalent for $10.6 billion to strengthen its oncology drug development capabilities.
BLOOMBERG06/09, 02:01 PM
Related assets
- GSK
- NUVL
Coming up for GSK
Explore next
Latest GSK news
WSJ07/29, 07:12 PM
WSJ Markets publishes a Health Care Market Talk roundup covering Argenx, GSK, and EssilorLuxottica.
WSJ07/17, 11:43 PM
FirstSquawk07/17, 03:33 PM